A review of German insurance data found no long-term increase in death risks tied to treatment with paclitaxel-coated devices, raising further questions about a meta-analysis that sent shockwaves through the industry late last year.
In the latest study, a team led by University Hospital Muenster, Germany, senior physician Eva Freisinger examined more than a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?